Form 4: Raphael Pharmaceuticals CEO Shlomo Pilo Acquires 200,000 Shares and Warrants
SEC Form 4
Raphael Pharmaceuticals CEO Shlomo Pilo reports acquiring 200,000 shares of common stock and warrants to purchase 100,000 shares at $0.50 per share and warrant.
Summary
- On March 2, 2025, Shlomo Pilo, CEO of Raphael Pharmaceuticals, acquired 200,000 shares of common stock.
- Pilo also acquired warrants to purchase 100,000 shares of common stock.
- The combined purchase price was $0.50 per share and accompanying warrant.
- Following the transaction, Pilo directly owns 3,983,701 shares of common stock.
- The warrants are immediately exercisable and expire on July 15, 2026.
- The exercise price of the warrant is $1.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The acquisition of shares and warrants could be seen as a positive sign of confidence by the CEO, but it's a relatively small transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal to the market.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence due to the CEO's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 03/02/2025 | Date of transaction: Acquisition of 200,000 shares of common stock and warrants to purchase 100,000 shares. |
| 03/11/2025 | Date of Form 4 filing. |
| 07/15/2026 | Expiration date of the warrants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.